NDA 021883 · Abbvie
Dalvance
Dalbavancin Hydrochloride · Intravenous
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Jan 13, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
May 23, 2014
Approved uses
3
Original approval plus efficacy supplements
Registered trials
28
9 Phase 3, 3 recruiting
FAERS reports
1,005
456 serious, 21 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 13, 2025.
1 INDICATION AND USAGE DALVANCE is a lipoglycopeptide antibacterial indicated for the treatment of adult and pediatric patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Gram-positive microorganisms. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of DALVANCE and other antibacterial drugs, DALVANCE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.2 ) 1.1 Acute Bacterial Skin and Skin Structure Infections DALVANCE ® is indicated for the treatment of adult and pediatric patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant isolates), Streptococcus pyogenes , Streptococcus agalactiae , Streptococcus dysgalactiae , Streptococcus anginosus group (including S. anginosus , S. intermedius , S . constellatus ) and Enterococcus faecalis (vancomycin susceptible isolates). 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of DALVANCE and other antibacterial agents, DALVANCE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Mechanism: Dalbavancin is an antibacterial drug [see Microbiology ( 12.4 )] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 22, 2021 Supplement 10 · Efficacy LabelLetter
- Jan 20, 2016 Supplement 3 · Efficacy · priority review ReviewLabelLetter
- May 23, 2014 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
1 products under this application
- DALVANCE · DALBAVANCIN HYDROCHLORIDE EQ 500MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Dalbavancin" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsPivotal-lookingCompleted
Durata Therapeutics Inc., an affiliate of Allergan plcIndustry
NCT01431339 · 739 participants · Start Jul 2011 · Primary completion Nov 2012
Drug: IV Dalbavancin; Vancomycin/Linezolid · For: Abscess; Wound Infection; Surgical Site Infection and 1 more
Sites: Montgomery, Alabama; Anaheim, California; Buena Park, California · 137 sites in all
- Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsPivotal-lookingCompleted
Durata Therapeutics Inc., an affiliate of Allergan plcIndustry
NCT02127970 · 698 participants · Start Apr 18, 2014 · Primary completion Mar 11, 2015
Drug: Dalbavancin; Dalbavancin-matching Placebo · For: Abscess; Wound Infection; Surgical Site Infection and 1 more
Sites: Montgomery, Alabama; Anaheim, California; Long Beach, California · 78 sites in all
- Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsPivotal-lookingCompleted
Durata Therapeutics Inc., an affiliate of Allergan plcIndustry
NCT01339091 · 573 participants · Start Mar 2011 · Primary completion Sep 2012
Drug: Dalbavancin; Vancomycin / Linezolid · For: Abscess; Wound Infection; Surgical Site Infection and 1 more
Sites: Anaheim, California; Azusa, California; Bellflower, California · 91 sites in all
- Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus AureusPivotal-lookingRecruiting
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT05117398 · 406 participants (planned) · Start Jun 23, 2023 · Primary completion Sep 23, 2025
Drug: Dalbavancin administration; Standard antibiotic therapy · For: Catheter Bacteremia; Staphylococcus Aureus Infection
Sites: Garches, France; Périgueux, France
AllerganAbbVie (ABBV)
NCT02961764 · 313 participants · Start Nov 29, 2016 · Primary completion Mar 29, 2019
Drug: Usual Care; Dalbavancin · For: Acute Bacterial Skin and Skin Structure Infections
Sites: Phoenix, Arizona; Sylmar, California; Hartford, Connecticut · 11 sites in all
- Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.Pivotal-lookingRecruiting
Fundación Pública Andaluza para la gestión de la Investigación en SevillaAcademic, hospital or other
NCT06423898 · 284 participants (planned) · Start Oct 9, 2024 · Primary completion Jul 31, 2027
Drug: Ampicillin plus ceftriaxone in continuous infusion; Ampicillin plus ceftriaxone in intermittent infusion of 14 days, after which the treatment may be changed · For: Endocarditis, Infective
Sites: Alava, Spain; Barakaldo, Spain; Barcelona, Spain · 18 sites in all
- DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus BacteremiaPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT04775953 · 200 participants · Start Apr 22, 2021 · Primary completion Oct 6, 2023
Drug: Cefazolin; Dalbavancin and 4 more · For: Staphylococcal Bacteraemia
Sites: Birmingham, Alabama; Sacramento, California; Torrance, California · 24 sites in all
- Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSAPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT02814916 · 199 participants · Start Mar 30, 2017 · Primary completion Jan 1, 2024
Drug: Dalbavancin; Vancomycin and 4 more · For: Methicillin-Resistant Staphylococcus Aureus; Bacterial Infections; Staphylococcal Skin Infections
Sites: Mobile, Alabama; Phoenix, Arizona; La Palma, California · 84 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use148
- rash96
- back pain59
- pruritus59
- drug ineffective58
- nausea57
- dyspnoea54
- vomiting51
- hypersensitivity46
- erythema42
- urticaria39
- pyrexia35
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 13 |
| 2015 | 18 |
| 2016 | 47 |
| 2017 | 78 |
| 2018 | 52 |
| 2019 | 75 |
| 2020 | 100 |
| 2021 | 82 |
| 2022 | 94 |
| 2023 | 80 |
| 2024 | 145 |
| 2025 | 127 |
| 2026 | 94 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Dalvance (Dalbavancin HCl)
2024 spending
$17.9M
Beneficiaries
1,693
3,699 claims
Per beneficiary
$10,553
$663.48 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $6,073,007 |
| 2021 | $7,892,769 |
| 2022 | $10,515,065 |
| 2023 | $13,677,432 |
| 2024 | $17,866,532 |
Part B: Dalvance (Dalbavancin HCL) · HCPCS J0875
2024 spending
$59.5M
Beneficiaries
7,974
15,829 claims
Per beneficiary
$7,460
2024 ASP limit $15.45 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $34,199,278 |
| 2021 | $44,071,351 |
| 2022 | $47,053,003 |
| 2023 | $54,207,841 |
| 2024 | $59,483,378 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis.
Leanza GM, Rando E, Frondizi F, et al. · Infection 2025 · Systematic Review
- Dalbavancin for infective endocarditis: A systematic review of effectiveness, safety, and dosing.
Chaldoupis AE, Petrakis V, Ioannou P, et al. · Eur J Clin Microbiol Infect Dis 2026 · Systematic Review
- Systematic review and meta-analysis on the safety of dalbavancin.
Monteagudo-Martínez N, Solís-García Del Pozo J, Ikuta I, et al. · Expert Opin Drug Saf 2021 · Comparative Study, Meta-Analysis
- Gateways to clinical trials.
Bayes M, Rabasseda X, Prous JR · Methods Find Exp Clin Pharmacol 2006 · Clinical Trial
- Dalba Got Back? Use of Dalbavancin for the Treatment of Vertebral Osteomyelitis.
Streifel AC, Strnad LC, Sikka MK, et al. · Open Forum Infect Dis 2024 · Clinical Trial
- Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis.
Carrothers TJ, Chittenden JT, Critchley I · Clin Pharmacol Drug Dev 2020 · Clinical Trial, Phase II, Clinical Trial, Phase III
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.